# Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2017

- Company: [Purple Biotech LTD.](/companies/ppbt.md) (CIK 1614744)
- Form: 20-F
- Filed: 2018-03-05
- Accepted by EDGAR: Mar 5, 2018, 09:32 ET
- Period: 2017-12-31
- Accession: 0001213900-18-002558
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1614744/000121390018002558/f20f2017_kitovpharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1614744/000121390018002558/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2017-01-01 to 2017-12-31 | −$12.1m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2017-01-01 to 2017-12-31 | $12.3m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Operating cash flow | 12 months, 2017-01-01 to 2017-12-31 | −$8.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2017-01-01 to 2017-12-31 | $13.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2017-12-31 | $3.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2017-12-31 | $8.0m | ifrs-full:CurrentAssets |
| Total assets | at 2017-12-31 | $14.2m | ifrs-full:Assets |
| Current liabilities | at 2017-12-31 | $4.1m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2017-12-31 | $7.3m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2017-12-31 | 0 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1614744/000121390018002558/f20f2017_kitovpharma.htm

Filed Mar 5, 2018.
Source: SEC EDGAR, the filing index for accession 0001213900-18-002558. Last ingested by Listed: Nov 11, 2026, 03:47 ET. No prices; not investment advice.